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Abstract
To identify interactions a nucleoside analog library (NAL) consisting of 45 FDA-approved nucleoside analogs was screened
against 23 enzymes of the human nucleotide metabolism using a thermal shift assay. The method was validated with
deoxycytidine kinase; eight interactions known from the literature were detected and five additional interactions were
revealed after the addition of ATP, the second substrate. The NAL screening gave relatively few significant hits, supporting a
low rate of ‘‘off target effects.’’ However, unexpected ligands were identified for two catabolic enzymes guanine deaminase
(GDA) and uridine phosphorylase 1 (UPP1). An acyclic guanosine prodrug analog, valaciclovir, was shown to stabilize GDA to
the same degree as the natural substrate, guanine, with a DTagg around 7uC. Aciclovir, penciclovir, ganciclovir, thioguanine
and mercaptopurine were also identified as ligands for GDA. The crystal structure of GDA with valaciclovir bound in the
active site was determined, revealing the binding of the long unbranched chain of valaciclovir in the active site of the
enzyme. Several ligands were identified for UPP1: vidarabine, an antiviral nucleoside analog, as well as trifluridine,
idoxuridine, floxuridine, zidovudine, telbivudine, fluorouracil and thioguanine caused concentration-dependent stabilization
of UPP1. A kinetic study of UPP1 with vidarabine revealed that vidarabine was a mixed-type competitive inhibitor with the
natural substrate uridine. The unexpected ligands identified for UPP1 and GDA imply further metabolic consequences for
these nucleoside analogs, which could also serve as a starting point for future drug design.
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Introduction
Nucleotide metabolism is one of the major metabolic pathways
in cells. Nucleotides are not only the building blocks for DNA and
RNA but also key regulators and intermediates in a wide range of
cellular signalling and other metabolic processes. Nucleotides are
synthesized by either the de novo pathways or the salvage pathways
where nucleobases, nucleosides and deoxynucleosides are recycled
from nutrients or from degraded DNA, RNA and nucleotides. To
provide appropriate pool sizes of nucleotides in particular cellular
states, nucleotide metabolism is highly regulated by feedback
binding of pathway intermediates. For example, binding of
effectors such as nucleoside products or intermediates in nucleo-
tide metabolism to regulatory sites of key enzymes often provides
negative feed-back regulation, but in some cases may activate these
enzymes. Due to the fundamental role of nucleotides in cellular
metabolism, the enzymes of nucleotide metabolism constitute
important anti-proliferative targets for treatment of cancers or for
immunosuppressant therapy. Also, more than half of currently
approved antiviral drugs are nucleoside-based analogs [1–3].
Nucleoside analogs used in antiviral and anticancer chemotherapy
are prodrugs which require activation by cellular enzymes to their
active forms before reaching the intended target enzymes. Due to
the similarity in chemical structure of natural nucleosides and
nucleotides to the nucleoside analogs (NAs) used as drugs, there is
a potential for cross-reactivity with enzymes along their metabolic
pathways. For example, NAs could inhibit enzymes of nucleotide
metabolism by binding within the active sites. Alternatively, they
might also bind to regulatory sites and thus serve as inhibitors or
activators. One example is gemcitabine, which in its diphosphate
form binds to and inhibits ribonucleotide reductase. Other
examples are fluorouracil and floxuridine, which after conversion
to fluorodeoxyuridine monophosphate, inhibit thymidylate syn-
thase via a covalent interaction [4]. These interactions are
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37724considered to be important for the therapeutic effect but these
compounds can also act as polymerase chain terminators by
selective depletion of nucleotide (dNTP) pools and/or upon
incorporation into the nucleic acid chain.
In the present study we have addressed the possible cross-
reactivity of NAs with enzymes of human nucleotide metabolism
using an in vitro approach. Insights into novel cross-reactivity could
potentially explain some toxicity of NAs. In addition the
identification of novel interactions of NAs with enzymes in
nucleoside metabolism could render these compounds useful as
starting points for the development of novel, specific inhibitors that
target these enzymes. As a basis for the in vitro approach, more
than 30 enzymes of human nucleotide metabolism have been
purified to high homogeneity at the Structural Genomics
Consortium (SGC) Laboratory at the Karolinska Institute in
Stockholm. Furthermore, the structures of many of these enzymes
have been determined (sgc.ki.se/structures.html) [5].
The establishment of activity assays for a large number of
different enzymes is very challenging. Instead, a biophysical
binding assay was used to determine the interaction of the
enzymes with nucleoside analogs. Thermal shift assay (TSA) was
used, where binding is detected by the thermal stabilization of
proteins due to interaction with the ligand. There are several
potential formats for this assay including fluorescence- and light
scattering-based methods [6,7]. One advantage is that detection of
protein melting temperature using these assays can be done in a
high throughput format on multi-well plates and require relative
small amounts of protein sample. Similar approaches have been
used to screen protein kinases [8] and sulphotransferases [9]
toward panels of inhibitors and substrates. In these cases, many of
the compounds were already known to interact with members of
the families, due to significant sequence conservation of residues in
their active sites, cross-reactivates were expected.
We have designed a nucleoside analog library (NAL) containing
45 FDA (U.S. Food and Drug Administration)-approved nucleo-
side drugs. This library was screened against 23 selected enzymes
in human nucleotide metabolism using a light scattering-based
TSA [10]. In contrast to large scale TSA-based screening on
protein kinases and sulphotransferases mentioned above, our
enzyme collection is composed of a wide range of structural
enzyme families and therefore contains a highly divergent set of
active sites and effector binding sites. The TSA approach was
validated by the well-characterized enzyme, deoxycytidine kinase
(dCK) which is known to activate many NAs. Most of NAs did not
display significant off target effects using the TSA. However,
unexpected stabilizing ligands were identified for two proteins:
guanine deaminase (GDA) and uridine phosphorylase 1 (UPP1),
which were further analyzed by using biochemical and structural
means. Together this work established TSA as a useful strategy for
screening libraries against en ensemble of diverse enzymes within
pathways, as well provide new information on prodrug cross
reactivity, mechanism of side effects as well as rationale for future
drug design targeting the nucleotide metabolism.
Results and Discussion
Selection of Compounds to be Included in the
Nucleoside Analog Library (NAL)
A library of NAs was designed using two criteria: the compound
should be approved by the FDA as a pharmaceutical and the
compound should contain a natural or modified nucleobase,
nucleoside or nucleotide. Given these criteria, a search was
performed using Drugbank [11,12]. A total of 47 compounds were
identified and two of them, enprofylline and pentostatin, could not
be readily purchased. Thus, the nucleoside analog library
contained 45 compounds and is in the following referred to as
the NAL, although some compounds are nucleobase and
nucleotide analogs. The compounds included in NAL are listed
in Table S2 with their common name and IUPAC name. These
compounds are primarily used to treat different types of cancers or
viral infections caused by HIV, hepatitis B, hepatitis C, herpes
simplex virus type 1, herpes simplex virus type 2 and varicella
zoster virus [1–3,13,14].
Nucleotide Metabolism Enzyme Library
The proteins investigated here are listed in Table 1. They
constitute enzymes of human nucleotide metabolism, for most of
which expression and purification conditions have been estab-
lished at the SGC-Stockholm-Karolinska Institute. Many of the
proteins were also recently structurally characterized at SGC
(http://www.thesgc.org/structures) [5]. Most of the proteins
selected during expression and purification optimization proce-
dure contain all their functional domains but with small
truncations in the C- and N-terminus. A few of the proteins
(CTPS2, RRM1, UMPS (1) and UMPS (2)) contain individual
functional domains from larger multiple-domain enzymes
(Table 1). Information on gene name, full enzyme name, GenBank
ID, accession number, EC number, construct size, the part of
nucleotide metabolism in which the enzyme is involved and Tagg
for enzymes in the absence of ligands is given in Table 1. The
enzymes are numbered, which corresponded to the number in
Figure 1. However, this list of enzymes is not a complete list of all
enzymes in nucleoside and nucleotide metabolism, for example,
purine nucleoside phosphorylase and adenosine deaminase, which
are important enzymes in the metabolism of several nucleoside
and nucleobase analogs used in this study, are for technical reasons
not included.
Criteria for Thermal Shift Assay
A thermal shift assay based on light scattering was used to
measure enzyme-ligand binding. Normally when proteins melt
they rapidly form aggregates and this is detected by light scattering
[10]. The aggregation temperature (Tagg) measured correlates well
with the melting-temperature of the proteins [15]. Binding of
ligands most often increases the thermal stability e.g. the Tagg of
the proteins [15]. Positive DTagg values therefore indicate that a
compound acted as a potential ligand for a protein. Negative
DTagg values are also sometimes observed, which indicate that a
compound either destabilizes the folded protein by e.g. releasing a
stronger binding ligand or binds to a protein in its unfolded state
or on the path to the unfolded state. Ligands which form covalent
adducts or metal-coordinated ligands may also lead to negative
DTagg values. DTagg above 1uC may indicate specific binding of a
compound to a protein and was used as initial criteria in this study
[10]. For validation concentration-dependent response curves of
DTagg were established. In specific cases such as the control
enzyme dCK, DTagg below 1uC were still reporting on binding of
known substrates/ligands. In the end different enzymes showed
different root-mean-square deviation of the response which was
used as an additional criteria for prioritizing compounds for
further analysis. Compounds exhibiting a DTagg value above
0.5uC were further examined by concentration-dependent re-
sponse curve in order to validate whether they are ligands.
‘‘Fingerprints’’ for each enzyme screened with NAL was
determined, and in many cases addition of a second known
substrate or product was used to provide further complementing
information [15].
Screening of a Nucleoside Analog Library
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37724Figure 1. The DTagg values for the 23 enzymes screened against NAL. The enzymes are numbered: 1 ADSS2, 2 ADSL, 3 BPNT1, 4 CMPK2, 5
CTPS2, 6 DCTD, 7 DPYS, 8 GART, 9 GDA, 10 GMPR2, 11 GMPS, 12 ITPA, 13 NT5C2, 14 NT5C3, 15 NUDT16, 16 PAICS, 17 PRTFDC1, 18 RRM1, 19
UCK1, 20 UMPS (1), 21 UMPS (2), 22 UPB1, 23 UPP1, 24 UPP2. DTagg represents the difference between Tagg of a protein in the presence and
absence of a compound. The DTagg values are given as color codes based on DTagg calculated from two values within the same screen. The maximum
average mean deviation for DTagg is 0.5uC. However, in some cases, one of the values has been disregarded due to inappropriate curve fitting
parameters. In total of 1080 measurements 44 have either one value missing (8) or an average mean deviation greater than 0.5uC (36).
doi:10.1371/journal.pone.0037724.g001
Screening of a Nucleoside Analog Library
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dCK is an enzyme of the salvage pathway and converts
deoxycytidine (dCyd), deoxyadenosine (dAdo) and deoxyguano-
sine (dGuo) into their corresponding monophosphates, with dCyd
as the preferred substrate. Both UTP and ATP function as
phosphate donors and the kinetic patterns differ depending on the
phosphate donor used. The enzyme is feedback inhibited by its
distal end product, deoxycytidine triphosphate (dCTP) [16]. From
a clinical perspective, dCK activates several anticancer and
antiviral drugs used in therapy. Among these are lamivudine,
cytarabine, cladribine, gemcitabine, fludarabine, zalcitabine,
vidarabine, nelarabine, decitabine, clofarabine, emtricitabine,
azacytidine and didanosine [16–18].
dCK was tested against the NAL at two different concentrations
(100 and 500 mM) in the presence and absence of 0.1 and 1 mM
ATP (Table 2). Interaction between dCK and ATP (1 mM) alone
gave a DTagg value of 21.6uC.
The compounds shown to increase the thermal stability of dCK
can be divided into two groups: 1) emtricitabine, lamivudine,
decitabine, clofarabine, cladribine, gemcitabine, cytarabine and
fludarabine and 2) zalcitabine, entecavir, azacytidine, vidarabine
and nelarabine. Interactions between dCK and group 1 ligands
increased dCK thermal stability with DTagg $1uC even in the
absence of ATP, with cladribine as an exception. In the presence
of ATP DTagg values were significantly increased. Group 2 ligands
produced mostly negative DTagg values and only in the presence of
1 mM ATP the DTagg values were positive, but they were still
,1uC, which was the detection limit. These ligands ranked
directly after the group 1 ligands in the full screen with 45 NAs,
indicating that these thermal shifts, although relative small, can be
assumed to be relevant. For both groups the relative shifts
observed at 500 mM, either with or without ATP, were between 3
and 5uC for group 1 ligands and more than 1uC for group 2
ligands (Table 2). Thus, all compounds in Table 2 are interacting
with dCK, as have previously been shown in biochemical studies
[16–18].
Some of the interactions were further evaluated and a
concentration-dependent stabilization was observed for all group
1 compounds, including cladribine, in the absence of ATP.
However, in case of fludarabine a negative concentration-
dependent curve was obtained, i.e. from DTagg of 2uCa t
100 mM to just below 0uC at 1000 mM (data not shown). None
of the group 2 compounds exhibited positive concentration-
dependent curves in the absence of ATP. The fact that the thermal
shifts were greater when ATP was added, albeit the thermal shift
with ATP alone was negative (at 0.5 mM ATP, DTagg was 20.8uC
and at 1 mM ATP, DTagg was 21.6uC), indicated cooperative
binding of the substrates as expected. It is interesting to note that
the TSA approach allows for direct detection of interaction
between dCK and both substrates, e.g. nucleoside and ATP, in
spite of their transient nature, albeit it is not clear if stabilization is
due to binding of a ternary complex, the products or both.
In summary, we were able to identify eight ligands (emtricita-
bine, lamivudine, decitabine, clofarabine, cladribine, gemcitabine,
cytarabine and fludarabine) for dCK. A second set of potential
ligands (zalcitabine, entecavir, azacytidine, vidarabine and nelar-
abine) was detected with relative thermal shifts above 1uC. All of
these NAs, except for entecavir, are known to be activated by
dCK. Therefore, after careful multiple measurements, a threshold
(DTagg) as low as 0.5uC had allowed identification of known
substrates which gave concentration dependent responses of
thermal shifts for dCK.
Screening of 23 Enzymes of the Nucleotide Metabolism
Library Toward NAL
All 23 enzymes were exposed to 100 and 500 mM of the
nucleoside analogs. Results are shown for the enzymes with
500 mM of the compounds (Fig. 1). Several enzymes, i.e. GART,
GDA, GMPR2, ITPA, NUDT16 and UPP1, were stabilized with
a DTagg .1uC in the presence of several ligands. Destabilization
(negative DTagg value) was observed with several enzymes
including CMPK2, DPYS, ITPA, NUDT16 and RRM1. It was
unexpected that azathioprine caused destabilization of RRM1
Table 2. Mean DTagg (uC) for dCK.
NAs 500 mMN A( +1 mM ATP) 500 mMN A( +0.1 mM ATP) 500 mM NA 100 mMN A
Emtricitabine 9.11 4.21 1.65 1.23
Lamivudine 8.32 3.39 0.93 0.97
Decitabine 7.29 4.73 4.33 2.56
Clofarabine 5.45 1.66 1.68 0.37
Cladribine 5.44 1.29 20,33 0.33
Gemcitabine 5.22 3.65 3.87 2.31
Cytarabine 4.93 2.98 2.74 1.33
Zalcitabine 0.95 20.22 20.61 20.15
Entecavir 0.83 21.29 21.33 20.97
Azacytidine 0.76 20.93 21.06 20.32
Vidarabine 0.63 21.02 22.44 20.11
Nelarabine 0.50 22.13 21.64 21.14
Fludarabine 0.12 0.38 0.95* 20.09
Tagg 53.8 54.4 54.0 53.8
The Mean DTagg was based on two samples within the screen. The average deviation from mean value was less than 60.5uC. The NAs were listed according to the
largest increase in thermal shifts (DTagg) in the presence of 500 mMN Aa n d1m MA T P .T agg for dCK in each screening is presented. * Indicate that the result is based on
one value.
doi:10.1371/journal.pone.0037724.t002
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dependent (de)stabilization experiments were performed with
GART, GDA, UPP1, GMPR2, ITPA and RRM1 at 100, 200,
300, 500 and 1000 mM of the nucleoside analog to monitor
potential saturation effects. Significant concentration dependent
effects of the ligands were observed with UPP1, GDA and RRM1
and the detailed results are described below. Both GMPR2 and
ITPA showed significant shifts with many ligands but no
concentration-dependent stabilization was observed. In addition
ITPA, but not GMPR2, showed an unusual sensitivity to DMSO,
even small variations in the DMSO concentration induced
thermal shifts. Due to the lack of hits with concentration-
dependent stabilization these two enzymes were not investigated
further.
From the study of dCK and NAL, it is clear that addition of
ATP reveals interactions with additional ligands. This approach
was used in cases where the enzymes use ATP, PRPP, NADPH,
ribose-1-phosphate, free phosphate ion (Pi) or pyrophosphate as a
second substrate or product. PRTFDC1, UMPS (1), ITPA,
NUDT16, GMPR2, UPP1, UPP2, CMPK2, CTPS2 and PAICS
were all screened in the presence of a second substrate/product. A
significant effect was observed only with UPP1 (see below). In the
following section we will specifically describe and discuss the
results obtained with UPP1, GDA and RRM1.
Uridine Phosphorylase 1 (UPP1)
UPP1 catalyzes the reversible reaction of uridine and Pi into
uracil and ribose-1-phosphate. Human UPP1 follows a steady-
state ordered bi-bi kinetic mechanism. It is suggested that Pi binds
to the free enzyme followed by uridine. Uracil then leaves the
ternary complex, followed by dissociation of ribose-1-phosphate
[19].
It is well established that UPP1 can convert fluorouracil into
fluorouridine, which is subsequently phosphorylated into fluor-
ouridine monophosphate by uridine/cytidine kinase [20,21]. The
metabolites of fluorouracil can disrupt RNA synthesis or inhibit
thymidylate synthase activity, the latter which is essential for DNA
synthesis and repair [21]. Toxic effects on normal tissues exerted
by fluorouracil metabolites can be minimized by a high dose of
uridine. One alternative approach to raise the intracellular
concentrations of uridine is to inhibit UPP1 [22]. Benzylacyclour-
idine (BAU) is a potent inhibitor of UPP1, and has been
investigated in clinical trials [23]. Calabresi et al. showed that
BAU could reduce zidovudine-induced bone marrow toxicity in
mice [24].
Screening of UPP1 with 500 mM NAL revealed several
potential ligands; vidarabine, trifluridine, idoxuridine, thioguanine
and cladribine. Addition of ribose-1-phosphate to the protein as a
second substrate identified zidovudine, fluorouracil and telbivu-
dine as additional potential ligands. Addition of ribose-1-
phosphate further stabilized UPP1 in the presence of following
ligands: vidarabine, trifluridine, zidovudine and telbivudine
(Table 3). To investigate saturation effects, concentration-depen-
dent stabilization of UPP1 was tested with floxuridine, thiogua-
nine, vidarabine, cladribine, idoxuridine, trifluridine, zidovudine,
telbivudine, fluorouracil and uridine. Uridine, the natural
substrate, was used as a reference. Concentration-dependent
stabilization of the enzyme was found with uridine, vidarabine,
trifluridine, idoxuridine and fluorouracil (Fig. 2A). In Figure 3, the
structures of ligands, as well as the DTagg values for the enzyme at
1 mM compound are shown. Vidarabine, an adenosine analog,
with a DTagg of 7.9uC at 1 mM, is the ligand that most efficiently
stabilizes UPP1 and it is clearly superior to the natural substrate
uridine that gave a DTagg of 3.7uC. Idoxuridine and trifluridine
stabilized the enzyme to the same extent as uridine. Concentra-
tion-dependent stabilization curves for telbivudine, zidovudine,
floxuridine and thioguanine exhibited the same degree of
stabilization as fluorouracil. Cladribine did not stabilize the
enzyme in a concentration-dependent manner, and is therefore
not regarded as a ligand.
Vidarabine, the ligand stabilizing UPP1 the most; was further
studied to determine the nature of vidarabine interaction with
UPP1, whether it is a substrate, activator or inhibitor of the
enzyme. When vidarabine was incubated with the enzyme, no
conversion of vidarabine to adenine was observed by reverse phase
HPLC analysis even after prolonged incubation. Therefore, a
further characterization of vidarabine as an inhibitor of UPP1 was
carried out. Three different vidarabine concentrations were used
in the presence of five different uridine concentrations. The rates
of substrate conversions to uracil as a function of uridine
concentration (Fig. 4) revealed a mixed-type inhibition with a Ki
value of 390 mM and a Ki/Km of 4.88. Thus, vidarabine have a
relatively high affinity for the UPP1 enzyme. These kinetic data
suggested that vidarabine binds independently of the natural
substrate but altered the affinity of the enzyme for uridine,
resulting in the observed mixed-type inhibition. We have not been
able to determine a structure of this complex so we cannot
conclude whether this is an allosteric effect or direct effect.
To our knowledge the interactions between UPP1 and the
ligands revealed in this study, i.e. those involving vidarabine,
idoxuridine, trifluridine, telbivudine, zidovudine and thioguanine
have not been reported earlier, except for fluorouracil and
floxuridine [20]. Further detailed studies of their mode of binding
and effect on enzyme catalysis, such as those performed for
vidarabine, should shed further light on their mode of action.
Together the identification of these novel UPP1 ligands may have
implications for the mechanism of activation and side effects of
NAs, as well as aid in future development of nucleoside analogs.
Guanine Deaminase (GDA)
GDA catalyzes the irreversible deamination of guanine to
xanthine [25]. The enzyme is highly expressed in liver, brain,
kidney and placenta [26,27]. Furthermore, GDA is also involved
in the regulation of dendrite development as a positive regulator
by modulating guanine concentrations [26]. The presence of GDA
activity in serum has been used as a diagnostic marker for liver
disease [28]. The structure of human GDA was solved in complex
with xanthine in 2007 at SGC (Pdb id: 2UZ9). Since GDA is
involved in purine metabolism, as well as in the regulation of
dendrite formation, it has been suggested as a potential drug target
for example in the treatment of cognitive disorders [29].
All compounds exhibiting a DTagg value greater than 0.5uC
were further evaluated. Thioguanine, ganciclovir, aciclovir,
penciclovir, valaciclovir, flucytosine and idoxuridine showed
concentration-dependent stabilization of GDA similar to guanine
(Fig. 2B), however, flucytosine and idoxuridine did not give a dose-
dependent stabilization of GDA. Both valaciclovir and guanine
exhibited a positive DTagg < 7uC at 1000 mM concentration,
followed in decreasing order by thioguanine, acyclovir, penciclo-
vir, ganciclovir and mercaptopurine. The chemical structures and
DTagg values of these compounds are shown in Figure 5.
In order to elucidate the molecular mechanism for the thermal
shift data the structure of GDA with valaciclovir bound within the
active site was determined at 2A ˚ resolution from crystals where
GDA was co-crystallized in the presence of valaciclovir (Table S1).
The structure of GDA in complex with its product, xanthine, has
previously been determined and is available in the Protein Data
Bank (pdb-id: 2UZ9). When the GDA-xanthine structure is
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ment in the overall fold of GDA was observed. However, a
hydrophobic patch (including residues Leu99, Trp102 and
Leu103) in the GDA-valaciclovir structure is slightly displaced in
order to accommodate the long hydrophobic tail of valaciclovir
(Fig. 6). The guanine base of valaciclovir makes similar interac-
tions as the xanthine base in the GDA-xanthine structure.
The relative DTagg values highlight on the importance of
different functional groups in these compounds. When comparing
the thermal shift for thioguanine and mercaptopurine, it is evident
that the loss of the amino group at the 2-position of the purine ring
of mercaptopurine, leads to less stabilization of GDA. Further-
more, replacement of O with S at 6-position also decreases the
binding of thioguanine and mercaptopurine to the enzyme,
suggesting that the loss of hydrogen bonds between the guanine
ring and Arg213 and Gln87 is the cause of weaker binding of the
analogs to GDA (Fig. 6). The thermal shifts obtained with acyclic
guanosine analogs suggest that both the length and hydrophobicity
of the sugar mimic play an important role in binding. As
demonstrated in the GDA-valaciclovir structure, the chain length
of valaciclovir matched the hydrophobic path enhancing the
stability of GDA, and the shorter chain length in acyclovir,
penciclovir and ganciclovir were associated with smaller thermal
shifts. The increased hydrophilicity of ganciclovir most likely
explained the decreased thermal shifts as compared with that of
penciclovir (Fig. 5).
The finding that valaciclovir and other acyclic guanosine
analogs are ligands for GDA may have significant implication in
the metabolism of guanine, since GDA is responsible for the
catabolism of guanine and in regulation of guanine nucleotide
pools. About 80% of xanthine produced in mammals occurs via
guanine deamination. Valaciclovir and other acyclic guanosine
analogs may act as substrates or inhibitors of GDA, and thus,
affect GDA activity. Further studies are needed in order to clarify
the effect of these analogs on GDA activity and the role of GDA in
the metabolism of acyclic guanosine analogs.
Thioguanine, but not mercaptopurine, has previously been
reported as a weak substrate for GDA [30,31]. Whether side
effects observed in treatment of various herpes virus infections
could be due to altered guanine metabolism require further
investigation. The knowledge gained in this study may stimulate
drug development programs designed to find new substrates or
inhibitors for GDA.
Ferna ´ndez et al. performed in silico screening with human GDA
(PDB id: 2UZ9) and 188 guanine analogs [32]. A number of
potential ligands, including caffeine, were identified, and some of
them were tested in biochemical assays using rabbit GDA as a
model enzyme. Many compounds tested exhibited good inhibitory
effects in the mid-micromolar range. It was suggested that longer
extensions at position C2 of the purine ring would increase affinity,
due to additional hydrophobic interactions [32]. In our study,
caffeine had no effect on the thermal stability of human GDA. Our
TSA assay and structural analysis instead demonstrated that a
longer unbranched chain at position N9 of the purine base
increased the thermal stability. Only a few overlaps between the
list of 188 guanine analogs and our NAL are present. One
example was thioguanine, which was identified as a ligand using
TSA. By using in silico screening, this compound only ranked at
position 17 out of the 188 guanine analogs [32]. An explanation
for this is that the in silico approach do not allow for
conformational modulations of the proteins upon ligand binding,
whereas this might be required as exemplified by the structure of
GDA-valaciclovir in this study.
Figure 2. Concentration-dependent stabilization of UPP1 (A) in
the presence of uridine, vidarabine, idoxuridine, trifluridine
and fluorouracil; GDA (B) in the presence of guanine,
valaciclovir, aciclovir, thioguanine, penciclovir, ganciclovir
and mercaptopurine; and concentration dependent destabili-
zation of RRM1 (C) in the presence of azathioprine.
doi:10.1371/journal.pone.0037724.g002
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Human ribonucleotide reductase (RR) plays an important role
in the de novo pathway of nucleotide metabolism. RR synthesizes
four deoxyribonucleoside diphosphates (dNDPs) by reducing
NDPs into their dNDP forms [33]. RR in humans is composed
of R1 and one of the two R2 subunits [34]. The expression of the
R2 subunit is tightly regulated both at the transcriptional and post-
translational levels. RR is able to maintain a balanced dNTP pool
within the cell, based on its sophisticated allosteric regulation.
RRM1 (name for the R1 subunit) contains three nucleotide
binding sites; the catalytic site and two allosteric sites. One
allosteric site is the activity site, which binds either ATP or dATP,
and functions as an on-off switch. The specificity site is the other
allosteric site, where ATP, dATP, dTTP or dGTP binds and alter
the activity of the enzymes for the four substrates, CDP, UDP,
GDP or ADP. The activity site is located in the N-terminus formed
by four a-helices [33–35]. Since RRM1 investigated here is a
truncated version, missing the first 74 amino acid residues, the
activity site is absent.
No significant positive stabilization of RRM1 was seen from any
member of the NAL. The destabilization of RRM1 by azathio-
prine, however, was concentration-dependent (Fig. 2C). We have
Figure 3. Ligands of UPP1 and mean DTagg with 1000 mM NA.
doi:10.1371/journal.pone.0037724.g003
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destabilization may be due to specific binding of the ligand
(Larsson and Nordlund, unpublished). Azathioprine is a prodrug
of mercaptopurine with an imidazole ring attached to the 6-thiol
group. Mercaptopurine destabilized RRM1 also, but only to a
lesser degree. Mercaptopurine-diphosphate is a substrate for
ribonucleotide reductase where it is activated to the deoxy form
before incorporation into DNA. It is possible that the azathioprine
precursor also interacts with the enzyme although this interaction
remains to be confirmed in further detail.
Conclusions
Few cross reactivities were observed between the 23 enzymes
investigated within the nucleotide pathway and the 45 FDA-
approved NAs. However, we identified interactions between
vidarabine, trifluridine, idoxuridine, zidovudine, telbivudine,
fluorouracil, floxuridine, thioguanine and UPP1. Furthermore,
vidarabine was found to be a mixed-type inhibitor of UPP1, which
is suggestive of an independent binding of both the uridine
substrate and the vidarabine ligand to the enzyme. Interactions
were detected between GDA and valaciclovir, aciclovir, penciclo-
vir, ganciclovir, thioguanine and mercaptopurine. UPP1 and
GDA bind nucleoside and nucleobase, respectively. This is
probably one reason why we were able to identify interactions
with these two enzymes, since our NAL consists of both
nucleosides and nucleobase analogs.
In order to make more comprehensive screen toward enzymes
within the nucleotide pathway, we suggest that a full library of all
enzymes in nucleoside and nucleotide metabolism and a complete
library of NAs, NAMPs, NADPs and NATPs should be used. If a
second substrate is necessary, as a first binder or activator, the
enzyme should be screened in the presence of this, thereby
obtaining the ‘‘full fingerprint’’ of the enzyme, as observed in case
of dCK and ATP. This approach would probably generate a more
extensive view of the cross-reactivities between nucleotide metab-
olism pathway enzymes and NAs and probably reveal additional
binding of phosphorylated nucleoside adducts to these enzymes.
Materials and Methods
Nucleoside Analog Library
The following compounds for the NAL screening were
purchased from Sigma: adefovir dipivoxil, adenosine, allopurinol,
azacytidine, azathioprine, caffeine, clofarabine, cytarabine, deci-
Table 3. Mean DTagg (uC) for UPP1.
NA DTagg (NA+R1P) DTagg (NA only)
Vidarabine 6.17 4.10
Trifluridine 3.78 1.26 *
Idoxuridine 1.72 1.31 *
Thioguanine 0.86 0.65
Zidovudine 0.64 20.39
Fluorouracil 0.59 0.42
Telbivudine 0.29 20.52
Tagg 56.7 57.0
The average deviation from mean value is less than 60.5uC.
*Indicates that deviation is greater than 60.5uC. Tagg of UPP1 in the absence of
NA is listed. The concentration of NA was 500 mM and R1P (ribose-1-phosphate)
was 1 mM.
doi:10.1371/journal.pone.0037724.t003
Figure 4. Kinetic analysis of UPP1 using Lineweaver-Burk plots. Uridine was used as substrate (50 to 375 mM) and vidarabine was as inhibitor
at 500 mM (?), 250 mM (?), and 100 mM( m) and 0 mM( X).
doi:10.1371/journal.pone.0037724.g004
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abine, theobromine, theophylline, thioguanine, trifluridine, vala-
ciclovir, vidarabine and zalcitabine. Cladribine and floxuridine
were purchased from Calbiochem. Abacavir sulfate, capecitabine,
famciclovir, penciclovir, pemetrexed and telbivudine were ob-
tained from Toronto Research Chemicals. Emtricitabine, enteca-
vir, tenofovir and valganciclovir were supplied by Moravek
Biochemicals Inc. Mercaptopurine was purchased from Fischer
Scientific and cidofovir was purchased from Bosche Scientific.
Aciclovir, didanosine, fludarabine, ganciclovir, gemcitabine,
lamivudine, pentoxyfylline, ribavirin, stavudine and zidovudine
were purchased from the European Directorate for the Quality of
Medicines.
Enzyme Preparations
Genes were obtained from the National Institutes of Health
Mammalian Gene Collection (for accession numbers, see Table 1)
except for the dCK construct, which was a kind gift from Drs. Liya
Wang and Elena Sjuvarsson, SLU, Sweden [36]. Each gene was
amplified and inserted into an appropriate vector, contained either
an N- or C-terminal His-tag. Vectors containing the correct insert
were transformed into an E. coli expression host and stored at
280uC until further use.
Figure 5. Ligands of GDA and mean DTagg with 1000 mM NA.
doi:10.1371/journal.pone.0037724.g005
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medium containing antibiotics and grown overnight at 37uC. Cells
from overnight cultures were used to inoculate TB or LB medium
(750 ml to 4.5 l) supplemented with antibiotics. Approximately
50 ml of Breox antifoam (Cognis Performance Chemical UK Ltd)
was added to each flask. Cultures were grown at 37uC until an
OD600 of 1.2 to 1.5 was obtained; this was followed by a cooling
period of 1 h at 18uC in a water bath. Expression was induced by
addition of 0.5 mM isopropyl-?-D-galactoside and incubation
overnight at 18uC. The cells were harvested the following morning
by centrifugation (55006g, 20 min, 4uC). The resulting cell pellet
was stored at 280uC.
Cells were disrupted either by sonication or high-pressure
homogenization (TC5-0612W-332 from Stansted fluid power Ltd)
and cell debris removed by centrifugation (49 0006g, 20 to
60 min, 4uC). The supernatant was decanted and filtered through
a 0.45 mm syringe filter. Proteins were purified on an A ¨KTAprime
system (GE Healthcare) in a two-step process, including an IMAC
Ni-charged column (1 to 5 ml HiTrap Chelating HP (GE
Healthcare) and gel filtration column (Superdex 75 or 200). The
IMAC column was equilibrated with IMAC wash buffer 1
(20 mM HEPES, 500 mM NaCl, 10% glycerol, 10 mM imidaz-
ole, 0.5 mM TCEP, pH 7.5). Protein was applied and washed
with IMAC wash buffer 1 and 2 (20 mM HEPES, 500 mM NaCl,
10% glycerol, 25 mM imidazole, 0.5 mM TCEP, pH 7.5). Bound
protein was eluted from the IMAC column with IMAC elution
buffer (20 mM HEPES, 500 mM NaCl, 10% glycerol, 500 mM
imidazole, 0.5 mM TCEP, pH 7.5) and automatically loaded onto
the gel filtration column, which had been equilibrated with gel
filtration buffer (20 mM HEPES, 300 mM NaCl, 10% glycerol,
0.5 mM TCEP, pH 7.5). Fractions were analyzed by SDS-PAGE
and those containing the target proteins were pooled and
concentrated using a centrifugal filter device with a 10,000
molecular weight cut off (MWCO). The identity of each protein
was confirmed by mass spectrometry. Additional information can
be obtained from http://www.thesgc.org/structures.
Thermal Shift Assay Using Differential Static Light
Scattering
All compounds were dissolved in 100% dimethylsulfoxide
(DMSO) as 20 mM stocks, except for cidofovir which was
solubilized in buffer A (20 mM HEPES pH 7.5, 300 mM NaCl,
1 mM MgCl2) and stored at 220uC. The compounds were diluted
in buffer A at final concentrations of 100 and 500 mM in 96-well
screening plates and stored at 280uC, and thawed immediately
before use.
Before measuring protein aggregation using the TSA and
differential static light scattering (DSLS), proteins were centrifuged
for 5 min in order to remove possible protein aggregates. Protein
was added to each well to a final concentration of 0.2 mg/ml
(assuming a molecular weight of 35 kDa , 6 mM), and transferred
to 384-well optical bottom plates (#242764; Nunc, Rochester,
NY, USA). The samples were run in duplicate on each screening
plate. The experiments were performed using a Stargazer-384
(Harbinger Biotechnology and Engineering Corporation, Toron-
to, Canada) with an assay volume of 50 ml per well. 45 mlo f
mineral oil (#M1180, Sigma-Aldrich) was added to each well, to
prevent evaporation. The plates were heated at 1uC?min-1, and
images were taken every 0.5uC in the range 25 to 80uC.
Intensities, as a measure of light scattering from protein
aggregation, were converted from the images and plotted as a
function of temperature. The midpoint of transition, the aggre-
gation temperature (Tagg) [10,15], was calculated using the
manufacturer’s software (Harbinger Biotech). DTagg represents
the calculated difference between Tagg of a protein in the presence
of a compound and under control conditions without the
compound. In some cases, proteins were screened in the presence
of a co-substrate/product, which was added to the protein solution
before adding it to the screening plate.
Kinetic Studies of UPP1 with Vidarabine as Inhibitor
Reaction mixtures containing different concentrations of
uridine (50, 100, 175, 250 and 375 mM), vidarabine (0, 100,
250 and 500 mM) and 1.6 ng recombinant UPP1 in a total
volume of 100 ml reaction buffer (10 mM Tris–HCl pH 7.6,
3 0 0m MN a C l ,1m ME D T A ,2m MK H 2PO4/K2HPO4)w e r e
incubated at room temperature. After 10 min, the reaction
mixtures were heated at 95uC for 3 min to inactivate the
enzyme. The reaction products were separated on a reverse-
phase RP-8 column (Merck Chemicals Ltd) and quantified by
HPLC analysis (Alliance 2690, Waters). The separation of
uridine from uracil was performed by a linear gradient from
100% separation buffer (50 mM NaH2PO4, 5 mM heptane
sulfonic acid pH 3.2) to 60% separation buffer plus 40%
acetonitrile (3 min 100% separation buffer; 6 min linear gradient
of 100% separation buffer to 60% separation buffer plus 40%
acetonitrile; 6 min 60% separation buffer plus 40% acetonitrile,
followed by equilibration at 100% separation buffer). UV-based
detection of uridine and uracil was performed at 253 nm and the
retention time was 3.17 min (uridine), 2.50 min (uracil) and
10.15 min (vidarabine), respectively.
The data were fitted into Michealis-Menten equation using
double reciprocal plots and regression lines were made for each set
of data points. Mode of inhibition was deduced by Lineweaver-
Burk plots.
Crystallization, Data Collection and Structure
Determination of GDA
Crystals were obtained by the sitting drop vapor diffusion
method using a 96-well plate. Protein solution (15 mg/ml, 0.1 ml)
Figure 6. GDA in complex with valaciclovir. Amino acids that form
hydrogen bonds to the guanine base of valaciclovir are shown. The a-
helix containing the hydrophobic patch is superimposed with the
corresponding residues of the GDA-xanthine structure (black).
doi:10.1371/journal.pone.0037724.g006
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(0.1 ml) containing 20% PEG 6000, 100 mM HEPES pH 7.0 and
200 mM MgCl2 and the drops were equilibrated at 4uC. A
crystal was dipped into a cryo solution (100 mM HEPES pH 7.0,
200 mM MgCl2, 21% PEG 6000, 20% glycerol, 300 mM NaCl
and 1.8 mM valaciclovir) and flash-frozen in liquid nitrogen.
Data was collected at the Bessy beamline BL14-2 and processed
with XDS [37] and Scala [38]. For molecular replacement,
protein data bank (PDB) entry 2UZ9 was used as an input for
MOLREP [38]. Model building and refinement were performed
with COOT [39], REFMAC5 [40] and Phenix [41] (Table S1).
Superpositions were made using the SSM superposition algo-
rithm in COOT [39,42]. Structural representations were made
using PyMOL [43].
The coordinates and structure factors have been deposited to
the Protein Data Bank with the accession code 4AQL. All data
collection and refinement statistics are shown in Table S1.
Supporting Information
Table S1 Data and refinement statistics for GDA in complex
with valaciclovir.
(DOC)
Table S2 Common names and IUPAC names for NAs included
in the NAL.
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